Publication|Articles|November 16, 2026

Evidence-Based Oncology

  • December 2026
  • Volume 32
  • Issue Spec 14

Cencora to Acquire American Oncology Network, Expanding Footprint in Community Practices

Author(s)Mary Caffrey
Fact checked by: Kelly King
Listen
0:00 / 0:00

Key Takeaways

  • Cencora will acquire AON for a $2.4 billion enterprise value: $2.3 billion at closing plus up to $100 million in contingent value rights tied to specified conditions.
  • Equity rollover of up to 25% by certain stockholders could result in ~$1.7 billion paid for 75% ownership, with expected adjusted diluted EPS accretion in year two.
SHOW MORE

The $2.4 billion transaction would bring American Oncology Network's 350-plus providers into the management services platform Cencora built around OneOncology, extending its reach to 12 more states.

Cencora, Inc, has signed a definitive agreement to acquire American Oncology Network, Inc (AON), a physician-led network of more than 350 oncology providers across 21 states, in a deal that values AON at an enterprise value of $2.4 billion, the companies announced October 21, 2026.1

The transaction comes less than a year after Cencora closed its accelerated purchase of OneOncology2, and it continues a trend in which the nation’s largest drug distributors have bought into the management services organizations (MSOs) that support independent community oncology practices. According to Cencora, AON will add complementary capabilities to its MSO platform and expand its presence into 12 additional states.1

“The acquisition of AON will expand our physician-led oncology MSO and support of care in communities across the country,” Robert P. Mauch, PharmD, PhD, president and CEO of Cencora, said in a statement. “AON serves as a trusted partner to oncology practices with a differentiated solution set designed to meet their comprehensive needs. With the addition of AON to our leading MSO network, we will enhance our capabilities for independent practices, strengthening patient access to high-quality, cost-effective care, while fortifying our growth platform to drive long-term value for our stakeholders.”1

“Our physicians, clinicians and care teams, and the patients they serve, have always been at the heart of AON, and this agreement is about giving them more support, more resources and more time for patient care,” said Todd Schonherz, CEO of AON. “This is the next chapter of the same mission: high-quality, accessible cancer care delivered close to home, led by physicians who know their patients best. As an investor in AON since 2020 and a leader in oncology, Cencora understands that mission and will partner with us to accelerate that goal.”1

According to the statement, clinical decisions will continue to rest with AON’s physicians. Stephen “Fred” Divers, MD, AON’s chief medical officer, said the partnership would support dependable access to advanced therapies for patients in their own communities.1

What are the terms of the deal?

Cencora already holds approximately 4% of AON’s equity and will acquire the rest. The $2.4 billion enterprise value consists of $2.3 billion at closing and contingent value rights of up to $100 million, payable by Cencora if certain conditions are met. According to the announcement, some AON stockholders may roll over equity representing up to 25% of the company; if they do, Cencora expects to pay approximately $1.7 billion to reach 75% ownership. Cencora expects the deal to be accretive to adjusted diluted earnings per share in the second year after closing.1

The transaction requires regulatory clearances and approval by AON stockholders. AON’s board approved the agreement on the unanimous recommendation of a special committee of independent directors.1

AON, founded in 2018 and based in Fort Myers, Florida, has roots in Florida Cancer Specialists & Research Institute (FCS), which launched the MSO to bring its operational expertise to smaller practices; AON later separated from FCS.3

Is this Cencora’s first foray into community oncology?

Cencora, then AmerisourceBergen, took a 35% stake in OneOncology in April 2023 as part of a $2.1 billion deal with TPG. In December 2025, Cencora agreed to accelerate its purchase, buying shares from TPG and other shareholders for approximately $3.6 billion in a transaction that valued OneOncology at $7.4 billion. The deal closed in early February 2026, ahead of a second-quarter target, with OneOncology’s affiliated practices and management retaining a minority stake.2,4 OneOncology now counts 36 practice partners, including oncology and urology clinics.2

At the time of the closing, OneOncology CEO Jeff Patton, MD, told The American Journal of Managed Care® (AJMC®) that the governance terms reflected Cencora’s confidence in the physician-led model. “It shows their trust in allowing us to be physician-centric and physician-focused,” Patton said.2 He also described Cencora as a crucial partner as complex therapies such as bispecific antibodies move into community settings.2

How are distributors reshaping community oncology?

Cencora’s competitors have made similar moves. In August 2024, McKesson agreed to pay $2.49 billion for a 70% stake in Core Ventures, the business and administrative services organization formed by FCS, with physicians retaining about 30%; that deal closed in June 2025.5,6 Cardinal Health, meanwhile, has built Navista, its oncology practice alliance, which made several major personnel moves7,8 and acquired urology MSO Solaris Health for $1.9 billion through its multispecialty platform, The Specialty Alliance.3

Shifting reimbursement, value-based care demands, and the infrastructure needed for advanced therapies have pushed independent practices toward partners with capital and scale.6-8

References
  1. Cencora to acquire American Oncology Network to strengthen support of community oncology. News release. Cencora. October 21, 2026. Accessed November 16, 2026. https://www.cencora.com/newsroom/cencora-to-acquire-american-oncology-network
  2. Caffrey M. As Cencora closes with OneOncology, Patton says terms show “trust.” AJMC. February 5, 2026. Accessed November 16, 2026. https://www.ajmc.com/view/as-cencora-closes-with-oneoncology-patton-says-terms-show-trust-
  3. Caffrey M. Walcker named president of Cardinal’s The Specialty Alliance, with strengths in GI, urology. AJMC. June 17, 2026. Accessed November 16, 2026. https://www.ajmc.com/view/walcker-named-president-of-cardinal-s-the-specialty-alliance-with-strengths-in-gi-urology
  4. Cencora accelerates OneOncology acquisition, extending solutions offering for community oncology. News release. Cencora. December 15, 2025. Accessed November 16, 2026. https://investor.cencora.com/news/news-details/2025/Cencora-Accelerates-OneOncology-Acquisition-Extending-Solutions-Offering-for-Community-Oncology/default.aspx
  5. McKesson Corporation completes acquisition of Core Ventures. News release. McKesson Corp. June 3, 2025. Accessed November 16, 2026. https://www.mckesson.com/about-us/newsroom/press-releases/2025/mckesson-corporation-completes-acquisition-of-core-ventures/
  6. Caffrey M. Beyond McKesson and Florida Cancer Specialists, deals are reshaping community oncology. Am J Manag Care. 2024;30(Spec No. 11):SP870-SP873. doi:10.37765/ajmc.2024.89692
  7. Caffrey M. Wilfong joins Navista as chief medical officer: “We really want to partner with practices.”Am J Manag Care. 2026;32(Spec No. 5):SP186-SP187.
  8. Caffrey M. Jeff Hunnicutt to bring community oncology roots to new role at Navista COO. Am J Manag Care. 2026;32(Spec No. 11):SP632.

Related to this article

CAR T-cell therapy | Image: AdobeStock
In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."